Lewis Asset Management
DFTX icon

Lewis Asset Management’s Definium Therapeutics DFTX Stock Holding History

Lewis Asset Management’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-4,585
Closed -$216K – 231
2026
Q2 		$216K Buy
+4,585
New +$113K 0.08% 211

Other funds holding DFTX

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $33.4B AUM 56.97% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Lewis Asset Management's DFTX Position: Q3 2026 in Review

Lewis Asset Management sold out of Definium Therapeutics (DFTX) in Q3 2026, closing a stake of 4,585 shares — an estimated $216K sold.

Lewis Asset Management first reported a position in DFTX in Q2 2026 and held it in 1 quarter. The position peaked at $216K in Q2 2026. 253 funds tracked by Wall St. Rank hold DFTX as of Q3 2026.

  • Lewis Asset Management reported no remaining Definium Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Lewis Asset Management sold 4,585 Definium Therapeutics shares in Q3 2026, an estimated $216K.
  • Lewis Asset Management first reported a position in Definium Therapeutics in Q2 2026 and held it in 1 quarter.
  • Lewis Asset Management's Definium Therapeutics position peaked at $216K in Q2 2026.
  • 253 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2026.

Based on Lewis Asset Management's 13F filing for Q3 2026, filed 14 Oct 2026.